The employer PBM provisions: One employer PBM transparency provision in the CAA 2026 package calls for PBMs to send employer health plan fiduciaries detailed prescription benefits operations data. The ...

Late last week, the U.S. Department of Labor (DOL) filed an amicus brief urging the Third Circuit to uphold a lower court's dismissal in Barragan v. Honeywell Int'l Inc.

The average allowed amount for a patient with no chronic conditions was $1,590, while the average allowed amount for a patient with one chronic condition was nearly double, at $3,039.

The former employees argue that the company was involved in self-dealing and prohibited transactions under ERISA because it designed its own funds, picked the managers, decided how assets were ...

U.S. District Judge Brian Martinotti recently issued two rulings that let pharmacies, or "direct purchaser" plaintiffs, move ahead with claims against pharmacy benefit managers that were based on the ...

West Virginia began to license PBMs in 2020. In 2022, the state began to require insurers to pass all prescription drug rebates and other prescription drug discounts on to health insurance purchasers ...

"Employers have an opportunity to strengthen engagement by pairing competitive benefits with greater flexibility and support that helps people feel more secure," said Jake Spiegel, senior research ...

"Without real-time supply-chain visibility, teams are forced to make critical decisions with incomplete information." said Jeff Wagner vice president of pharmacy, respiratory care and ECMO services ...

About 46% of respondents said they somewhat or greatly preferred the idea of being able to choose from a long list of coverage providers and plan types.

The complaint, filed by the law firm Sanford Heisler Sharp McKnight, alleges that Bloomberg failed to remove two funds from its plan after they performed poorly for more than a decade.

Regulators accused the company of failing to make good on earlier promises to improve how it handles complaints.

Demand for obesity and metabolic therapies is accelerating deal activity as pharma companies shift from blockbuster drugs to platform control.